Work

Additional file 1 of Gp350-targeted CAR-T therapy in EBV-positive Burkitt lymphoma: pre-clinical development of gp350 CAR-T

Year: 2025

Type: article

Abstract: Supplementary Material 1. Figure S1 Schematic diagram of the anti-gp350 CAR structure. The CAR construct includes: IgHL (Immunoglobulin heavy chain leader signal sequence), scFv (single-chain variable fragment for specific antigen recognition), IgG4 hinge (for receptor flexibility), IgG1 Fc CH3 domain (for structure stabilization), CD28TM (CD28 transmembrane domain for membrane anchoring), CD28cyto (CD28 cytoplasmic domain for costimulatory signaling), and CD3ζ (CD3 zeta chain intracellular domain for primary T-cell activation signal). The restriction sites PmlI and BamHI are indicated.

Source: Figshare

DOI: 10.6084/m9.figshare.28386673

Authors: Wang, Jiajia, Wang, Huiping, Ding, Yangyang, Cao, Nengneng, Nan, Fengya, Wu, Fan, Li, Cong, Liang, Xue, Xiao, Meng, Guo, Jinjing, Gao, Zhimai, Yan, Li, Zhou, Tielin, Li, Yanli, Zhai, Zhimin

Institutions: The People's Hospital Tongling, Second Affiliated Hospital of Anhui Medical University, First Affiliated Hospital of Anhui Medical University, Fuyang Maternity and Child Health Care Hospital

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W6902270974

FWCI:

Cites:

Cited by:

Related to: